Current Research Studies
Phase 1b/2, randomized, double-blind, placebo-controlled, multi-center study of STMC-103H in neonates and infants at high-risk for developing allergic disease
ADORE (STMC-103H-102)
What is the goal of the study?
Primary indication is to see is STMC-103H, prevents allergic disease in at-risk neonates. The primary objective of this study is to assess the safety, tolerability, and preliminary efficacy of STMC-103H compared to placebo in neonate and infant subjects at high risk for development of allergic disease.
Who can participate in the study?
Please contact the study team listed below to learn more.